Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan.

Abstract

S-4661 is a methylcarbapenem antibiotic newly developed in Japan. We evaluated the combined actions of carbapenems, including S-4661 and vancomycin or teicoplanin, against 27 strains of methicillin-resistant Staphylococcus aureus (MRSA) isolated from the blood of patients admitted to Keio University Hospital, using the checkerboard technique. The minimum inhibitory concentrations (MICs) were determined by the Mueller-Hinton agar method. Most of the strains were highly resistant to carbapenems. Synergy with S-4661, panipenem, meropenem or imipenem, and vancomycin was detected against 92% of the strains tested. Synergy with S-4661, panipenem, meropenem or imipenem, and teicoplanin was detected against 74% of the strains tested. The results of our study suggest that combination therapy of vancomycin or teicoplanin with any of S-4661, panipenem, meropenem, or imipenem would be effective for severe infections due to MRSA strains that are resistant to carbapenems.

• Authors: Yoshio Kobayashi
• Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy (J Infect Chemother) Vol. 11 Issue 5 Pg. 259-61 (Oct 2005) ISSN: 1341-321X [Print] Netherlands
• PMID: 16258825 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Carbapenems
• Teicoplanin
• Vancomycin
• Doripenem

Topics

• Anti-Bacterial Agents (pharmacology)
• Bacteremia (microbiology)
• Carbapenems (pharmacology)
• Doripenem
• Drug Resistance, Bacterial
• Drug Synergism
• Drug Therapy, Combination
• Humans
• Japan
• Methicillin Resistance
• Microbial Sensitivity Tests (methods)
• Staphylococcal Infections (microbiology)
• Staphylococcus aureus (drug effects)
• Teicoplanin (pharmacology)
• Vancomycin (pharmacology)